Adam Hauben

Oncology/ Philadelphia Sports

[Adam Hauben @ahauben4]

@rickybottalico Schmidt 10 gold gloves Rollins 4. Similar AVG.

Schmidt, Harper, Carlton and maybe Rollins

[Adam Hauben @ahauben4]

@975BestShowEver Add context. Lou Gehrig was HR for every 16.2. Schmidt was and is one of best 3rd baseman in baseball history

[Adam Hauben @ahauben4]

@975BestShowEver Harper also does more for this team then Rollins did. One of the best team leaders and Philadelphia athletes of his era.

One amazing stat for Mike Schmidt is that he hit a HR every 15.5 at bats. Harper 1 HR every 17.5 at bats.

[Adam Hauben @ahauben4]

@975BestShowEver There is no way Rollins is ahead of Schmidt. He loses on almost all statistical comparison. Schmidt had 10 Gold gloves, Rollins 4. Schmidt had also a higher lifetime batting average. Not even close.

I go Schmidt then Harper.

[Philadelphia Phillies @Phillies]

Still thinking about this

[Caris Life Sciences @carisls]

Caris welcomes Dr. George W. Sledge, Jr. (@GeorgeSledge51) as Chief Medical Officer. Dr. Sledge brings over 30 years of oncology research and practice experience to the company and will oversee Caris’ Medical Affairs group.
Learn more: https://t.co/M4TtXnuaKu

[Caris Life Sciences @carisls]

Caris is sponsoring a symposium at this year’s International Gynecologic Cancer Society (@IGCSociety) annual meeting focused on exploring the importance of comprehensive #molecularprofiling in gynecologic cancer. Join our expert panel October 1st. #IGCS2022

[Inky Johnson @inkyjohnson]

G rind
R elentless
I ntegrity
N now
D ependable

[Razelle Kurzrock, MD @Dr_R_Kurzrock]

If it’s a target, it’s a pan-cancer target

[Adam Hauben @ahauben4]

@chadinabhan Leaving NRG as we speak. I wasn’t thinking. Should have connected while out here.

[Chase Wasson @chase_wasson]

Appreciate the Division Chief of Gynecologic Cancer @StephensonCC @OUHealth ⬇️ @DebbieRic23 stopping by @carisls @ASCO @ahauben4 🎯 🧬 #WinTheDay

[chadi nabhan MD, MBA, FACP @chadinabhan]

Such an honor to have @AmerCancerCEO as our @carisls POA keynote speaker to discuss the vision of the American Cancer Society to improve on patient care, precision medicine, and mitigate disparities.
@ASCO #ASCO22

[Christopher Darus MD @topherdarus]

Thank you @carisls for bringing attention to the importance of molecular testing. It is such an honor to care for brave women like Diane. #ovariancancer

[Adam Hauben @ahauben4]

Excellent review of the role of NGS in clinical care

[David B. Solit, MD @DSolit]

The prospective clinical MSKCC NGS cohort is now >50,000 samples sequenced. Thanks to the hundreds of physicians, laboratory technicians, data scientists, nurses and support staff @sloan_kettering who have made this initiative possible. A few thoughts on what we have learned.

[Caris Life Sciences @carisls]

Nationally recognized @DukeCancer and @CedarsSinai, become the 32nd and 33rd member of Caris’ collaborative network focused on expanding the application of precision medicine in cancer treatment.
https://t.co/XMBuNafkvP

[Targeted Oncology @TargetedOnc]

The last FDA approval of 2019 was also the first approved BRCA targeted therapy in pancreatic cancer, marking GI oncology another exciting field that had many advances in 2019. Which field did you find most exciting in 2019 in terms of FDA approvals?
#oncoalert #FDANews #oncology

[Caris Life Sciences @carisls]

"We do more cancer-specific, treatment-geared IHC work than any other laboratory. It's only at that volume that you can see the broad heterogeneity between cancer cases and know what's important." - Dr. David Spetzler, #CarisLS President & Chief Scientific Officer.

[OncLive.com @OncLive]

The average survival of patients with mCRC hovers around 3 years, but by understanding where the tumor originated and the increasing array of molecular markers, clinicians have a better chance of optimizing outcomes #crcsm https://t.co/SK3atc8Bsx

[Fox Chase Cancer Center @FoxChaseCancer]

An informative synopsis from @urotoday of Dr. @Robert_Uzzo's presentation at #ASCO19 where he discusses the role of cytoreductive nephrectomy in the post-CARMENA era.
https://t.co/6658l16NK5 @FCUroOnc

[Wafik S. El-Deiry, MD, PhD, FACP @weldeiry]

Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer | NEJM a new standard of care for patients with metastatic pancreatic cancer & germline BRCA mutations; all such patients must be tested https://t.co/edM6jmMTwV